Skip to main content

Table 2 Descriptive analysis of full economic evaluations for liver metastases from colorectal cancer (lmCRC)

From: Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review

Author, year, publication type and country

Patient’s characteristics

Treatments

Analysis type/Model

Perspective/Time horizon

Cost

Outcomes

Comparators

Microspheres

Y-90 TARE vs. BSC

       

Bester, 2013 [23]

Communication at congress

United Kingdom

lmCRC unresectable hepatic-predominant, refractory to chemotherapy a

Y-90 TARE vs. BSC

Y-90 resin microspheres

CUA / Markov

Payer /

ND

Direct cost (medical):

Y-90 TARE (acquisition, preparation, and procedure), BSC treatment, monitoring, AE management and palliative care.

Cost, LYG, QALY, ICER (€/LYG), ICUR (€/QALY) and WTP (£30.000/QALY)

Cosimelli, 2013 [24]

Communication at congress

Italy

lmCRC unresectable hepatic-predominant, refractory to chemotherapy a

Y-90 TARE vs. BSC

Y-90 resin microspheres

CUA / Markov

Payer /

ND

Direct cost (medical):

Y-90 TARE (acquisition, preparation, and procedure), additional chemotherapy, AE management and palliative care.

Cost, LYG, QALY, ICER (€/LYG), ICUR (€/QALY) and WTP (€50.000/QALY)

Pennington, 2015 [25]

Original article

United Kingdom

lmCRC unresectable hepatic-predominant, refractory to chemotherapy b

Y-90 TARE vs. BSC

Y-90 resin microspheres

CUA / Markov

Payer /

lifetime

Direct cost (medical):

Y-90 TARE (preparation and procedure), BSC treatment, monitoring, additional treatment, AE management and palliative care.

Cost, LYG, QALY, ICER (€/LYG), ICUR (€/QALY) and WTP (£30.000/QALY)

Brennan, 2020 [26]

Original article

United Kingdom

lmCRC unresectable hepatic-predominant, refractory/intolerant to chemotherapy b

Y-90 TARE vs. BSC

Y-90 resin microspheres

CUA / Markov

Payer/

Lifetime

Direct cost (medical):

Y-90 TARE (preparation and procedure), treatment, AE management and palliative care costs.

Cost, LYG, QALY, ICER (€/LYG), ICUR (€/QALY) and WTP

(£30.000/QALY)

Y-90 TARE vs. HAI

       

Loveman, 2014 [27]

Systematic review an economic evaluation United Kingdom

lmCRC surgically unresectable c

Y-90 TARE + HAI

vs.

HAI

Y-90 resin microspheres

CUA / Partitioned survival model

Payer and social/

Lifetime

Direct cost (medical):

Treatment, post- treatment, monitoring, and palliative care.

Cost, LYG, QALY, ICER (€/LYG), ICUR (€/QALY) and WTP (£30.000/QALY)

  1. AE: adverse event, BSC: best supportive care, CUA: cost-utility analysis, HAI: hepatic artery infusion with floxuridine, ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; QALY: quality-adjusted life years, lmCRC: liver metastases from colorectal cancer, LYG: life year gained; ND: no data, Y-90 TARE: transarterial radioembolization with yttrium 90; WTP: willingness-to-pay
  2. a. The sample size was not included in the analysis. b. The sample size reported in the analysis considered the retrospective data from Bester et al. 2012 [30] (Y-90 TARE n = 224; BSC = 51). c. The sample size reported in the analysis considered the clinical trial data from Grey et al. 2001 [32] (Y-90 TARE + HAI n = 36; HAI n = 34)
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us